AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23723457
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose oseltamivir (150 mg twice a day)
Trial: 23723457
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose oseltamivir (75 mg twice a day)
Trial: 23723457
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose oseltamivir
Trial: 23723457
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose oseltamivir
Trial: 21986780
Drug: Methylsulfonylmethane (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylsulfonylmethane (5 g daily) and boswellic acids (7.2 mg daily)
Trial: 19485978
Drug: pegylated‐interferon‐alpha2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) with amantadine (200 mg/daily)
Trial: 19485978
Drug: pegylated‐interferon‐alpha2a (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegylated‐interferon‐alpha2a (180 microg once weekly) plus ribavirin (1000‐1200 mg/daily) without amantadine
Trial: 17018656
Drug: Magnesium (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (300 mg elemental Mg per day in two divided doses)
Trial: 11166015
Drug: Standard dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dietary treatment (50% to 55% carbohydrate and 30% fat for 2 months)
Trial: 30919997
Drug: Denosumab treatment
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab treatment for up to 10 years
Trial: 22980301
Drug: Intravenous high
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous high dose of furosemide with hypertonic saline solution (HSS)
Trial: 11845758
Drug: CathSim Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CathSim Intravenous Training System (CathSim ITS)
Trial: 37879
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy for 12 weeks to reduce supine BP to 150/90 mmHg or below
Trial: 37879
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy for 12 weeks
Trial: 31843386
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg per day from the second to the twentieth day after surgery
Trial: 30744676
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with placebo herbal medicine
Trial: 21344144
Drug: CMV-immunoglobulins (Cytotect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV-immunoglobulins (Cytotect Biotest) for 12 months and short Ganciclovir or Valganciclovir therapy from 21th to 42th postoperative day followed by acyclovir up to 24 months
Trial: 15210261
Drug: Cognitive/behavioural group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive/behavioural group (cognitive preparation plus instruction in deep breathing exercises, tongue depressor task and swallowing technique)
Trial: 11171290
Drug: Oral continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral continuous combined HRT (Kliogest(R); 2 mg of oestradiol + 1 mg of norethisterone)
Trial: 3146197
Drug: L-asparaginase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase treatment
Trial: 1415455
Drug: Topical fibronectin
RxNorm normalized name: Fibronectin
DrugBank: Fibronectin (DB15150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fibronectin
Trial: 752876
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VM‐26 and CCNU at full dose
Trial: 752876
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VM‐26 and CCNU (half dose) with daily intake of procarbazine for 20 days
Trial: 752876
Drug: Radiotherapy after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy after three cycles of chemotherapy
Trial: 8843633
Drug: PRP‐T and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP‐T and DTP vaccines combined in the same syringe
Trial: 8843633
Drug: PRP‐T and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP‐T and DTP vaccines given separately
Trial: 25654354
Drug: Rifampin 10
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 10 mg/kg (Control)
Trial: 25489785
Drug: Rifapentine 15
RxNorm normalized name: rifapentine 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifapentine 15 mg/kg
Trial: 23850060
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion during an insulin tolerance test (ITT)
Trial: 16476920
Drug: Valdecoxib 20
RxNorm normalized name: valdecoxib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib 20 mg twice daily or once daily (with a 40-mg loading dose)
Trial: 16476920
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg 4 times daily
Trial: 9179510
Drug: 8 mg/day
RxNorm normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/day s.l. buprenorphine
Trial: 9179510
Drug: Naloxone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (10 mg 70 kg i.m.) during 8 mg buprenorphine maintenance
Trial: 8144233
Drug: Cobalt oxide
RxNorm normalized name: COBALT OXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobalt oxide (insoluble cobalt compound)
Trial: 3513714
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation by rotahaler
Trial: 3513714
Drug: Tilting the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilting the head back during inhalation and holding the breath for 10 seconds
Trial: 25155815
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavior therapy (CBT) for 9 weeks
Trial: 19685520
Drug: Intracoronary bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary bone marrow stem cell (BMSC) therapy at 4 to 7 days
Trial: 10793164
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral xemilofiban
Trial: 10793164
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of oral xemilofiban
Trial: 9395803
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg as a 1 ml injection 1 to 2 hours before operation
Trial: 9395803
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1 ml intramuscularly before operation
Trial: 9395803
Drug: Pethidine 50
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 50 mg as a 1 ml injection immediately after surgery
Trial: 9395803
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 1 ml intramuscularly immediately after surgery
Trial: 9395803
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose of pethidine given
Trial: 7954480
Drug: Moclobemide 150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 150 mg twice daily (b.i.d.)
Trial: 7954480
Drug: Moclobemide 300
RxNorm normalized name: moclobemide 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 300 mg three-times-daily (t.i.d.)
Trial: 7954480
Drug: Moclobemide 450
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 450 mg three-times-daily (t.i.d.)
Trial: 7954480
Drug: Moclobemide 150
RxNorm normalized name: moclobemide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide 150 mg b.i.d. and t.i.d. groups
Trial: 7483868
Drug: Hypocaloric nutrition
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypocaloric nutrition (glucose or xylitol/sorbitol-amino acid solutions)
Trial: 2090557
Drug: Intravenous streptokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous streptokinase (group A)
Trial: 3769194
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (group B)
Trial: 23789216
Drug: Qi-regulating, chest-relaxing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qi-regulating, chest-relaxing and blood-activating therapy integrated with some Western Medicines
Trial: 23789216
Drug: Simple and
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple and conventional Western Medicine alone
Trial: 21479913
Drug: Alendronate 70
RxNorm normalized name: ALENDRONATE 70MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 70 mg combined with vitamin D(3) 5,600 IU
Trial: 18379369
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with reduced-dose carboplatin (AUC 3) and gemcitabine (1250 mg/m on days 1 and 8)
Trial: 18379369
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with gemcitabine and low-dose carboplatin
Trial: 11789225
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Chinese herbal medicine combined with synchronous radio- and chemotherapy) in group A
Trial: 11789225
Drug: Non-synchronous radio-
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-synchronous radio- and chemotherapy in group C
Trial: 9212969
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits (Group H)
Trial: 8661572
Drug: IV glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV glucagon (1 mg)
Trial: 8273637
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg oral hyoscyamine sulfate
Trial: 2525326
Drug: Nicorandil (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (20 mg)
Trial: 10537782
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with benzoporphyrin derivative
Trial: 10537782
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy with tin ethyl etiopurpurin
Trial: 4044104
Drug: Caffeine trial
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine trial (5 mg caffeine/kg body weight)
Trial: 27530657
Drug: Selenium 200
RxNorm normalized name: SELENIUM 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium 200 µg daily as selenized yeast
Trial: 23963309
Drug: Low-dose drospirenone/estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose drospirenone/estradiol (0.25 mg/0.5 mg and 0.5 mg/0.5 mg)
Trial: 23963309
Drug: Estradiol (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol (0.3 mg)
Trial: 22882843
Drug: Rosuvastatin loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin loading before PCI (20 mg 12 hours before procedure, 10 mg 2 hours before procedure)
Trial: 22882843
Drug: No rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rosuvastatin treatment before PCI (control group)
Trial: 18216475
Drug: Pimecrolimus 1%
RxNorm normalized name: PIMECROLIMUS 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimecrolimus 1% cream applied twice daily for 8 weeks
Trial: 8556396
Drug: Early zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early zidovudine treatment (n = 170)
Trial: 8556396
Drug: Later zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Later zidovudine treatment (n = 168)
Trial: 24150216
Drug: F-SHAI (SHAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-SHAI (SHAI with fludarabine, 15 mg/m(2), 4 h before cytarabine)
Trial: 24150216
Drug: SHAI (cytarabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHAI (cytarabine, 1 g/m(2) bid, days 1‐2 and 8‐9; idarubicin 10 mg/m(2) daily, days 3‐4 and 10‐11)
Trial: 8858272
Drug: Yohimbine (5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (5.4 mg)
Trial: 20837887
Drug: Pyridostigmine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (60 mg)
Trial: 20837887
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pyridostigmine and yohimbine
Trial: 11562748
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with stem cell support
Trial: 11856590
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy in inflammatory breast cancer
Trial: 11856590
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy after conventional treatment
Trial: 10205193
Drug: Atropine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (15 microg/kg bolus, 4 microg/kg/h infusion)
Trial: 31831388
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy plus standard medical therapy
Trial: 28017524
Drug: 2 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg paricalcitol (PCT)/day for 12 weeks
Trial: 28017524
Drug: PCT treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT treatment
Trial: 8241702
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (100 mg per day)
Trial: 26780394
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 mg lactose)
Trial: 23171573
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g tannin-rich fiber (high-dose group, n = 13)
Trial: 23171573
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g (placebo group, n = 14)
Trial: 8968661
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days followed by 0.030 mg desogestrel for 7 days
Trial: 1601378
Drug: Causal pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Causal pharmacological treatment of disordered spermatogenesis
Trial: 28901214
Drug: Total dose
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dose infusion (TDI) of low molecular weight (LMW) iron dextran
Trial: 28901214
Drug: Oral iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral iron ferrous fumarate 60 mg elemental iron three times daily
Trial: 30660136
Drug: LSM &
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation "LSM &" based solely on the provided context. Drug abbreviations can vary and may not have a clear or standardized full generic name. Without more details about the specific drug or clinical trial, I cannot confidently provide the full generic name. The best I can suggest is to refer to the clinical trial documentation or consult a medical reference for more information about this particular drug abbreviation.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSM & n‐3 (EPA + DHA concentrate 1.5 g/day, containing 0.6 g EPA + DHA)
Trial: 22444781
Drug: Copper supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copper supplementation (2 mg copper/day as copper glycinate) for 8 weeks
Trial: 17571965
Drug: Very low-fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low-fat vegan diet supplemented with soy protein (58 g/day)
Trial: 12224093
Drug: KTP (532
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTP (532 nm) laser treatment
Trial: 10223495
Drug: Tolterodine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 0.5 mg twice daily
Trial: 9426760
Drug: Tolterodine 1
RxNorm normalized name: tolterodine 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 1 mg twice daily
Trial: 7799029
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (GSH) at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15‐minute period immediately before CDDP administration, and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Trial: 7799029
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution (placebo).
Trial: 26834282
Drug: Pumpless group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pumpless group (PL group: blood cardioplegia administration without roller pump)
Trial: 26834282
Drug: Roller pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roller pump group (RP group: blood cardioplegia administration with roller pump)
Trial: 19356420
Drug: Contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast agent use during dobutamine stress echocardiography (DSE)
Trial: 11875694
Drug: Intratumoural/intrapleural SRL172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intratumoural/intrapleural SRL172 (1 microg to 1 mg) and intradermal SRL172 (1 mg) with standard chemotherapy (mitomycin‐C: 8 mg m(‐2), vinblastine: 6 mg m(‐2), cisplatin: 50 mg m(‐2))
Trial: 11875694
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy (mitomycin‐C, vinblastine, cisplatin)
Trial: 11454528
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) - 5,000 IU intravenous bolus and continuous infusion of 18 IU/Kg/h (n=11)
Trial: 29482720
Drug: Low-dose piperaquine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose piperaquine (LD-PIP)
Trial: 28483414
Drug: P2-VP8-P[8] subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8-P[8] subunit rotavirus vaccine (30 μg)
Trial: 28483414
Drug: P2-VP8-P[8] subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8-P[8] subunit rotavirus vaccine (60 μg)
Trial: 28483414
Drug: P2-VP8-P[8] subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P2-VP8-P[8] subunit rotavirus vaccine and Placebo
Trial: 12627998
Drug: Pyridostigmine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (45 mg)
Trial: 8059699
Drug: Verapamil 240
RxNorm normalized name: verapamil 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 240 mg once daily
Trial: 26358841
Drug: OKZ 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKZ 60 mg/120 mg/240 mg every four weeks (Q4W)
Trial: 24751388
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine (10 μg/kg/hour)
Trial: 24751388
Drug: Intravenous nalbuphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nalbuphine (5 μg/kg/hour) and (10 μg/kg/hour)
Trial: 29059694
Drug: Manual Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Medicine (MM)
Trial: 15222407
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg)
Trial: 11461714
Drug: Treatment procedure
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment procedure with accounted measurement error in log-transformed total rapid eye movement (REM) activity counts
Trial: 9159697
Drug: Nortriptyline pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline pharmacotherapy
Trial: 26644225
Drug: Fixed Dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination (FDC) of ceftriaxone and sulbactam
Trial: 26644225
Drug: FDC (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC (3 g/24 h)
Trial: 1623444
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen injections
Trial: 31541364
Drug: Osteopathic Manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic Manual Therapy (OMT)
Trial: 12467746
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly oral prednisone (5mg/kg/dose)